News
Gelteq Expands Operations in United States with Appointment of Adam Bendell as President of U.S. Operations to Scale Domestic Business
-
NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ: GELS) (“Gelteq” or the “Company”), a clinical and science-based company that is focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products, announced today that it has expanded its operations in the United States with the appointment of Adam Bendell as President of U.S. Operations.11/12/2024
Gelteq Limited Closes US$5.2 Million Initial Public Offering
-
NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company”), a global biotechnology company that specializes in the formulation, development, and manufacturing of ingestible gel technology, announced today the closing of its initial public offering of 1,300,000 ordinary shares at a public offering price of US$4.00 per share. The ordinary shares commenced trading on the Nasdaq Global Market on October 29, 2024 under the symbol “GELS.”10/30/2024
Profitability
Dividends
Income Statement
Balance Sheet
Cash Flow Statement
Symbol Frequently Asked Questions
What is Gelteq Limited Ordinary Shares's stock price?
The price of Gelteq Limited Ordinary Shares (GELS) is 1.51 and it was updated on 2024-11-20 13:00:40.
Is Gelteq Limited Ordinary Shares (GELS) overvalued or undervalued?
Currently Gelteq Limited Ordinary Shares (GELS) is in undervalued.
News
| News |
|---|
 Gelteq Limited Prices US$5.2 Million Initial Public Offering
|
SEC Filings
Press Releases
| StockPrice Release |
|---|
GELS Ratings Summary
GELS Quant Ranking
